Loading
Ocular Disorders and Treatments / RNA Interference and Gene Delivery · Journal article
Science Advances · August 21, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a proof-of-concept study of a novel non-viral RNA delivery platform (CART) that achieves selective targeting to the corneal endothelium in mouse models, human donor cells in vitro, and a single non-human primate. The work demonstrates feasibility of the approach and redosing capacity, but provides no efficacy data, clinical outcomes, or systemic safety profiling required for clinical translation.
Preclinical mechanistic and proof-of-concept study. Laboratory mice; primary human donor corneal endothelial cells; one non-human primate. No clinical subjects enrolled.. Intervention: Charge-altering releasable transporter (CART) nanoparticles carrying diverse RNA cargoes (circular RNA, CRISPR/Cas9).
CART nanoparticles deliver diverse RNA cargoes (circular RNA, CRISPR/Cas9) selectively to corneal endothelium in mice Nanoparticles can be redosed and achieve corneal gene editing CART transfection demonstrated in human donor corneal endothelial cells in vitro and in one non-human primate in vivo
No quantitative efficacy endpoints, safety data, or comparative control arms reported No disease model or functional outcome assessment; no systemic toxicity or off-target delivery assessment reported
This work is at the stage of platform validation and does not yet provide evidence to guide clinical practice. It represents an early step toward potential future therapies for corneal dystrophies, contingent on successful safety and efficacy studies in larger animal models and humans.
Early-phase, uncontrolled mechanistic work demonstrating proof-of-concept for a novel delivery platform in mouse models, human cells in vitro, and one non-human primate, without efficacy endpoints or clinical outcome data.
As stated by the source record.
This work is at the stage of platform validation and does not yet provide evidence to guide clinical practice. It represents an early step toward potential future therapies for corneal dystrophies, contingent on successful safety and efficacy studies in larger animal models and humans.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
RNA therapies hold tremendous promise for treating genetic eye diseases. However, their development is limited by the lack of non-viral delivery platforms that can target specific ocular cell types. Here, we describe a charge-altering releasable transporter (CART) that delivers RNA selectively to the corneal endothelium, a non-regenerative cell layer whose dysfunction underlies several blinding conditions. We characterize the safety of CART-RNA nanoparticles in mice and show that they facilitate delivery of diverse RNA cargoes to the corneal endothelium, including circular RNA and CRISPR/Cas9. We verify that these nanoparticles can be redosed and apply them to achieve corneal gene editing. We further demonstrate CART transfection of corneal endothelial cells from a human donor in vitro and in a non-human primate in vivo, supporting the feasibility of clinical translation. Our findings establish CARTs as a platform for non-viral gene delivery to the eye, with the potential to treat corneal dystrophies and other vision disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.